Skip to search formSkip to main contentSkip to account menu

abciximab

Known as: 7E3, abciximab [Chemical/Ingredient], C7E3 
A Fab fragment of the chimeric monoclonal antibody 7E3 and inhibitor of the glycoprotein (GP) IIb/IIIa receptor, that blocks platelet aggregation… 
National Institutes of Health

Related topics

Related topics

20 relations
5 ML abciximab 2 MG/ML Injection [ReoPro]Angina, UnstableBrain NeoplasmsCerebral Infarction

Broader (4)

AnticoagulantsFab ImmunoglobulinsMonoclonal AntibodiesPlatelet Aggregation Inhibitors

Narrower (2)

ClotinabReoPro

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase.
Highly Cited
2004
Highly Cited
2004
Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with…
In this prospective randomized trial on patients with acute myocardial infarction (AMI) treated with primary percutaneous… 
Highly Cited
2001
Highly Cited
2001
Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting: A Safe and Effective Adjunctive Therapy
Background and Purpose— Abciximab has been shown to decrease periprocedural ischemic complications after coronary intervention… 
Highly Cited
1999
Highly Cited
1999
Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy.
Highly Cited
1999
Highly Cited
1999
Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk.
Highly Cited
1999
Highly Cited
1999
Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring Abciximab (ReoPro)
Transcatheter coronary interventions requiring abciximab (ReoPro) are associated with vascular access site complications. Several… 
Review
1999
Review
1999
Anticoagulation Monitoring during Cardiac Surgery
Anticoagulation Monitoring during Cardiac Surgery: A Review of Current and Emerging Techniques George Despotis;Glenn Gravlee… 
Review
1999
Review
1999
Binding of Abciximab to αVβ3 and Activated αMβ2 Receptors: With a Review of Platelet-Leukocyte Interactions
Introduction Murine monoclonal antibody 7E3, as well as the derivatives of 7E3 used in vivo [7E3-F(ab’)2, 7E3 Fab’, mouse/human… 
Highly Cited
1997
Highly Cited
1997
Tyrosine Phosphorylation of the Novel Protein-tyrosine Kinase RAFTK during an Early Phase of Platelet Activation by an Integrin Glycoprotein IIb-IIIa-independent Mechanism*
A key regulatory event controlling platelet activation is mediated through the phosphorylation of several cellular proteins by… 
Highly Cited
1991
Highly Cited
1991
A Monoclonal Antibody Against the Platelet Glycoprotein IIb/IIIa Receptor Complex Prevents Platelet Aggregation and Thrombosis in a Canine Model of Coronary Angioplasty
BackgroundThe comparative effects of aspirin and F(ab′)2 fragments of monoclonal antibody 7E3 against the platelet glycoprotein… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)